Filing Flows › Enanta Pharmaceuticals (ENTA) › Q2 FY26
Enanta Pharmaceuticals (ENTA) Q2 FY26 earnings results (second quarter fiscal 2026)
10-Q filed May 13, 2026
Enanta Pharmaceuticals (ENTA) reported revenue of $17.2M for the second quarter fiscal 2026 (Q2 FY26), +15% from a year earlier and -8% from the quarter before. Operating margin was -69.1%, net loss $13.1M (76.3% of revenue).
Enanta Pharmaceuticals, Q2 FY26: revenue $17.2M (+15% year over year), operating margin -69.1%, net loss $13.1M, operating cash flow −$7.2M. The chart follows the revenue to costs, profit and cash.
| Q2 FY26 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $17.2M | -8% | +15% |
| Operating profit | −$11.9M | — | — |
| Net earnings | −$13.1M | — | — |
| Operating cash flow | −$7.2M | — | — |
What changed
Revenue was $17.2M in Q2 FY26, up 15% year over year and down 8% from the previous quarter.
Operating costs exceeded revenue by $11.9M, an operating margin of -69.1%. Total costs fell 26% while revenue rose 15%. The quarter ended with a net loss of $13.1M, wider than the previous quarter's $11.9M loss.
Operating cash flow was −$7.2M. Non-cash charges added back $1.2M of depreciation and amortization and $3.7M of share-based compensation. Working capital and other items added $1.0M. Capital expenditures of $15K exceeded it, leaving free cash flow of −$7.2M.
Questions
What was Enanta Pharmaceuticals' revenue in the second quarter fiscal 2026?
Enanta Pharmaceuticals (ENTA) reported revenue of $17.2M for the second quarter fiscal 2026 (Q2 FY26), +15% from a year earlier and -8% from the quarter before.
Was Enanta Pharmaceuticals profitable in the second quarter fiscal 2026?
Operating loss was $11.9M (-69.1% of revenue) and net loss $13.1M.